Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | DGKA | P23743 | 1/20 | 0.63 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 1/20 | 0.60 |
| ▸ | TERT | O14746 | 3/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | PPARG | P37231 | 3/20 | 0.59 |
| ▸ | PPARD | Q03181 | 3/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.59 |
| ▸ | FAAH | O00519 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | FABP4 | P15090 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29119147 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL28936532 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL30592524 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL9348758 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL10084760 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL15027037 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL31203100 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL29119174 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL9348765 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD | |
| SCHEMBL29269579 | 1.00 | TSHR (0.64) | TSHRDGKAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860561-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2021237055-A1 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2019051289-A1 | LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL, CAPSID-FREE DNA VECTORS | GENERATION BIO CO. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20170267631-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9687448-B2 | Nucleic acid lipid particle formulations | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2575764-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20170101370-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-9593077-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9567296-B2 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2016-01-14 | — | — | US | disclosed |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | BANK OF AMERICA, N.A. | 2015-10-29 | — | — | US | disclosed |
| US-9012498-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2014089239-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086373-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | TSHR 2854/4885DGKA 336/4885PRKCE 3874/4885 |
| US-20170101370-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | NSUN3, METTL16, SOAT1 | TSHR 948/4885DGKA 3053/4885PRKCE 4310/4885 |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | NPC1L1, NPC1, CETP | TSHR 2889/4885DGKA 394/4885PRKCE 3720/4885 |
| US-20170267631-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | RNASEH1, L3MBTL1, NPC1L1 | TSHR 958/4885DGKA 2768/4885PRKCE 4549/4885 |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | TSHR 3260/4885DGKA 373/4885PRKCE 3513/4885 |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, NPC1L1, CETP | TSHR 3683/4885DGKA 423/4885PRKCE 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.